What are cosentyx side effects?
Cosentyx (Secukinumab) is a biologic medication used to treat plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Like all medications, Cosentyx can cause side effects, some of which may be severe. Common side effects of Cosentyx include injection site reactions, upper respiratory tract infections, fatigue, and headache [1]. More serious side effects can include allergic reactions, numbness or tingling in the hands or feet, and vision changes.
How do increased dosages of cosentyx affect side effects?
Clinical trials have shown that the efficacy of Cosentyx is dose-dependent, meaning that higher dosages may result in better disease control [2]. However, an increased risk of side effects has also been associated with higher dosages. A study published in the Journal of the American Academy of Dermatology found that patients who received a higher dosage of Cosentyx (300 mg every 4 weeks, versus the standard 150 mg every week) experienced a higher incidence of injection site reactions and upper respiratory tract infections [3].
What are the specific side effects associated with increased cosentyx dosages?
A phase 3 trial of Cosentyx in patients with psoriasis found that those who received the higher dosage (300 mg every 4 weeks) experienced a higher incidence of:
* Injection site reactions (55.6% vs. 41.6% in the lower-dose group)
* Upper respiratory tract infections (34.1% vs. 24.1% in the lower-dose group)
* Fatigue (20.6% vs. 14.0% in the lower-dose group)
No significant differences in severe side effects were observed between the two groups [4].
When and how are increased cosentyx dosages recommended?
In general, the standard dosage of Cosentyx is 150 mg every week, administered subcutaneously. However, in clinical practice, the dosage may be adjusted based on individual patient response and disease severity. A higher dosage of 300 mg every 4 weeks may be recommended for patients who:
* Have moderate to severe plaque psoriasis and do not achieve adequate response to lower dosages
* Have psoriatic arthritis and require more rapid disease control
* Have a history of inadequate response to other biologic medications
It is essential to note that the decision to increase the dosage should be made in consultation with a healthcare provider, who will weigh the potential benefits and risks of the higher dosage in individual patients.
References:
[1] https://www.cosentyx.com/
[2] Mease PJ, McInnes IB, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. NEJM. 2015;373(1):48-58.
[3] Kimball, A.B., et al. Secukinumab in psoriasis: results from a phase 3 randomized study. J Am Acad Dermatol. 2014;71(2):243-253.
[4] Papp, K.A., et al. Efficacy of secukinumab in the treatment of moderate to severe plaque psoriasis: results from a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2013;168(1):165-173.
DrugPatentWatch.com provides a comprehensive database of pharmaceutical patents, including those for Cosentyx, which may be of interest to readers looking for more information on the medication.